Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Review: AberrantEVI1expression in acute myeloid leukaemia
Adil Al Hinai, Peter J.M. Valk
British Journal of Haematology (2016) Vol. 172, Iss. 6, pp. 870-878
Open Access | Times Cited: 68

Showing 1-25 of 68 citing articles:

miR-22 Is a Novel Mediator of Vascular Smooth Muscle Cell Phenotypic Modulation and Neointima Formation
Feng Yang, Qishan Chen, Shiping He, et al.
Circulation (2017) Vol. 137, Iss. 17, pp. 1824-1841
Open Access | Times Cited: 183
Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy
Christine Duncan, Jacob Bledsoe, Bartosz Grzywacz, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 14, pp. 1287-1301
Closed Access | Times Cited: 38
MECOM-associated syndrome: a heterogeneous inherited bone marrow failure syndrome with amegakaryocytic thrombocytopenia
Manuela Germeshausen, Phil Ancliff, Jaime Estrada, et al.
Blood Advances (2018) Vol. 2, Iss. 6, pp. 586-596
Open Access | Times Cited: 95
Metabolic dependencies and vulnerabilities in leukemia
Marissa Rashkovan, Adolfo A. Ferrando
Genes & Development (2019) Vol. 33, Iss. 21-22, pp. 1460-1474
Open Access | Times Cited: 81
Identification of Potent, Selective, and Orally Bioavailable Small-Molecule GSPT1/2 Degraders from a Focused Library of Cereblon Modulators
Gisele Nishiguchi, Fatemeh Keramatnia, Jaeki Min, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 11, pp. 7296-7311
Open Access | Times Cited: 69
The Emerging Role of H3K9me3 as a Potential Therapeutic Target in Acute Myeloid Leukemia
Laura Monaghan, Matthew E. Massett, Roderick P. Bunschoten, et al.
Frontiers in Oncology (2019) Vol. 9
Open Access | Times Cited: 69
Murine Models of Acute Myeloid Leukaemia
Marwa Almosailleakh, Juerg Schwaller
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 2, pp. 453-453
Open Access | Times Cited: 58
The acquisition of molecular drivers in pediatric therapy-related myeloid neoplasms
Jason R. Schwartz, Jing Ma, Jennifer L. Kamens, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 54
MDS1 and EVI1 complex locus (MECOM): a novel candidate gene for hereditary hematological malignancies
Tim Ripperger, Winfried Hofmann, Jan Christoph Koch, et al.
Haematologica (2017) Vol. 103, Iss. 2, pp. e55-e58
Open Access | Times Cited: 50
PRMT5 regulates ATF4 transcript splicing and oxidative stress response
Magdalena M. Szewczyk, Genna M. Luciani, Victoria Vu, et al.
Redox Biology (2022) Vol. 51, pp. 102282-102282
Open Access | Times Cited: 25
Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML)
Thorsten Braun, Claude Gardin
Expert Opinion on Investigational Drugs (2017) Vol. 26, Iss. 7, pp. 803-811
Closed Access | Times Cited: 41
The expression level of EVI1 and clinical features help to distinguish prognostic heterogeneity in the AML entity with EVI1 overexpression
Xiaohang Ma, Mengge Gao, Riyan Cheng, et al.
Cancer Letters (2025) Vol. 615, pp. 217547-217547
Closed Access
RUNX1::MECOM rearrangement in myeloid neoplasm post cytotoxic therapy following sarcoma treatment: a case presentation and review of the literature
Miriam Sandnes, Øystein Sefland, Irini Ktoridou-Valen, et al.
Hematology (2025) Vol. 30, Iss. 1
Open Access
Clinical Outcomes in Acute Myeloid Leukemia Patients with High MECOM Expression Treated with Venetoclax-Based Regimens: A Single-Institution Retrospective Analysis
Hengwei Liu
Research Square (Research Square) (2025)
Closed Access
High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia
Wen Du, Jing He, Wei Zhou, et al.
Journal of Translational Medicine (2019) Vol. 17, Iss. 1
Open Access | Times Cited: 25
Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia
Sandra Kiehlmeier, Mahmoud‐Reza Rafiee, Ali Bakr, et al.
Leukemia (2021) Vol. 35, Iss. 11, pp. 3127-3138
Open Access | Times Cited: 20
Phenotypic heterogeneity in individuals withMECOMvariants in 2 families
Tetsuya Niihori, Reo Tanoshima, Yoji Sasahara, et al.
Blood Advances (2022) Vol. 6, Iss. 18, pp. 5257-5261
Open Access | Times Cited: 14
High EVI1 Expression Predicts Poor Outcomes in Adult Acute Myeloid Leukemia Patients with Intermediate Cytogenetic Risk Receiving Chemotherapy
Ya‐Zhen Qin, Ting Zhao, Hong‐Hu Zhu, et al.
Medical Science Monitor (2018) Vol. 24, pp. 758-767
Open Access | Times Cited: 22
t(3;8)(q26.2;q24) Often Leads to MECOM/MYC Rearrangement and Is Commonly Associated with Therapy-Related Myeloid Neoplasms and/or Disease Progression
Guilin Tang, Shimin Hu, Sa A. Wang, et al.
Journal of Molecular Diagnostics (2018) Vol. 21, Iss. 2, pp. 343-351
Open Access | Times Cited: 22
EVI1 induces autophagy to promote drug resistance via regulation of ATG7 expression in leukemia cells
Yuna Niu, Xue Yang, Yifei Chen, et al.
Carcinogenesis (2019) Vol. 41, Iss. 7, pp. 961-971
Closed Access | Times Cited: 21
CRISPR-mediated MECOM depletion retards tumor growth by reducing cancer stem cell properties in lung squamous cell carcinoma
Yuanyuan Ma, Bin Kang, Shaolei Li, et al.
Molecular Therapy (2022) Vol. 30, Iss. 11, pp. 3341-3357
Open Access | Times Cited: 12
The MDS and EVI1 complex locus (MECOM) isoforms regulate their own transcription and have different roles in the transformation of hematopoietic stem and progenitor cells
Miren Maicas, Iria Vázquez, Rafael Alis, et al.
Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms (2017) Vol. 1860, Iss. 6, pp. 721-729
Closed Access | Times Cited: 21
Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias
Eleonora Mäkelä, Karolina Pavic, Taru Varila, et al.
Clinical Cancer Research (2021) Vol. 27, Iss. 10, pp. 2848-2860
Open Access | Times Cited: 15
Comparison of myeloid neoplasms with nonclassic 3q26.2/MECOM versus classic inv(3)/t(3;3) rearrangements reveals diverse clinicopathologic features, genetic profiles, and molecular mechanisms of MECOM activation
Juehua Gao, Sandeep Gurbuxani, Taylor Zak, et al.
Genes Chromosomes and Cancer (2021) Vol. 61, Iss. 2, pp. 71-80
Closed Access | Times Cited: 15
3q26.2/MECOM Rearrangements by Pericentric Inv(3): Diagnostic Challenges and Clinicopathologic Features
Zhenya Tang, Wei Wang, Su Yang, et al.
Cancers (2023) Vol. 15, Iss. 2, pp. 458-458
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top